US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

WisdomTree Asia Local Debt Fund

44.39

+0.0000

Volume:- -

Turnover:- -

Market Cap:22.20M

PE:16.75

High:44.39

Open:44.39

Low:44.39

Close:44.39

Loading ...

Overview Company News Filings

Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results

Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment

Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues

Simply Wall St.

Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment

Lightwave Logic Announces Controlled Availability of Silicon Photonics Process Design Kit for Advanced Electro-Optic Polymer Integration

ACCESS Newswire

Closing Bell: Tech tumble and Trump tariffs trample Thursday

TSMC’s big US bet and China’s chip tool challenger

Financial Times

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

Ampol Limited (ASX:ALD) is favoured by institutional owners who hold 51% of the company

Simply Wall St.

Ampol's (ASX:ALD) Shareholders Will Receive A Smaller Dividend Than Last Year

Simply Wall St.

Ampol Full Year 2024 Earnings: EPS: AU$0.51 (vs AU$2.30 in FY 2023)

Simply Wall St.

Lam Research Ushers in New Era of Semiconductor Metallization with ALTUS® Halo for Molybdenum Atomic Layer Deposition

ALD SA (3AL) Receives a Hold from J.P. Morgan

Poxel Announces Results of its Combined General Meeting Held on February 11, 2025

Is Veeco Instruments Inc. (VECO) the Best Small-Cap Semiconductor Stock to Buy Now?

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

The one-year underlying earnings growth at Ampol (ASX:ALD) is promising, but the shareholders are still in the red over that time

Simply Wall St.

MSA Safety Showcasing Automatic Leak Detection and Monitoring Expertise at AHR Expo

Adisyn completes $10 million placement to drive AI enabling semiconductor innovation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"WisdomTree Asia Local Debt Fund","latestPrice":44.39,"timestamp":1567195200000,"preClose":44.39,"halted":0,"volume":0,"delay":0,"floatShares":400000,"shares":500000,"eps":2.65,"marketStatus":"Pre-Mkt","change":0,"latestTime":"04-28 06:39:56 EDT","open":44.39,"high":44.39,"low":44.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.65,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":44.39,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0.95455,"high":44.39,"amplitude":0,"preClose":44.39,"low":44.39,"week52Low":41.78,"pbRate":"--","week52High":46.6477,"institutionHeld":0,"latestPrice":44.39,"eps":2.65,"divideRate":0.021504,"volume":0,"delay":0,"ttmEps":2.65,"open":44.39,"prevYearClose":44.39},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528221425","title":"Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2528221425","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528221425?lang=en_us&edition=fundamental","pubTime":"2025-04-17 00:03","pubTimestamp":1744819380,"startTime":"0","endTime":"0","summary":"Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company’s activities. Event of default triggered by this non-adoption under the financing agreements with IRIS and IPF Partners, allowing each of them to request immediate redemption of the outstanding bonds they hold . With a cash position of EUR 2 million as of March 31, 2025, the Company is unable to repay IRIS and IPF Partners if they redeem their outstanding bonds, which significantly compromises its ability to continue as a going concern. Pending the outcome of ongoing negotiations with its creditors, the Company postpones the approval and release of its 2024 annual accounts. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-provides-financial-first-quarter-160300868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PXXLF","BK4139","ALD"],"gpt_icon":0},{"id":"2526739848","title":"Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526739848","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526739848?lang=en_us&edition=fundamental","pubTime":"2025-04-09 00:11","pubTimestamp":1744128660,"startTime":"0","endTime":"0","summary":"Approval by the Pharmaceuticals and Medical Devices Agency  in Japan enables TWYMEEG  to be prescribed to type-2 diabetic patients with moderate to severe renal impairment. This approval is based on the results of the Phase 4 TWINKLE study. Sumitomo Pharma to immediately start promoting the use of the product in this new patient population, further supporting efforts to maximize TWYMEEG opportunity in Japan. This regulatory milestone could also support Poxel’s strategy and ongoing discussions to develop and commercialize Imeglimin outside of Japan. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announces that the Pharmaceuticals and Medical Devices Agency  in Japan has approved the revision of TWYMEEG package insert for patients with renal impairment with eGFR  less than 45 mL/min/1.73m2.This","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-regulatory-approval-japanese-161100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","BK4139","PXXLF"],"gpt_icon":0},{"id":"2524474723","title":"Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2524474723","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524474723?lang=en_us&edition=fundamental","pubTime":"2025-04-03 07:01","pubTimestamp":1743634883,"startTime":"0","endTime":"0","summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 0.2x Ampol Limited ( ASX:ALD ) is definitely a stock worth...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/investors-arent-buying-ampol-limiteds-asxald-revenues","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD","ALD.AU","ISBC"],"gpt_icon":0},{"id":"2523570219","title":"Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2523570219","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523570219?lang=en_us&edition=fundamental","pubTime":"2025-03-31 13:00","pubTimestamp":1743397200,"startTime":"0","endTime":"0","summary":"Newly granted patent covers Imeglimin’s use in type-2 diabetic patients with renal impairment and has a patent term in Japan until 2039. This patent further supports Poxel’s strategy to maximize Imeglimin’s commercial potential in Japan and beyond. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announced that the Japanese Patent Office has granted Poxel a new patent  covering the use of Imeglimin in type-2 diabetic patients with moderate to severe renal impairment until 2039.Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare disorders. For the treatment of MASH, PXL065  met its primary endpoint in a streamlined Phase 2 trial . In r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-grant-patent-japan-050000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PXXLF","ALD"],"gpt_icon":0},{"id":"2522574597","title":"Lightwave Logic Announces Controlled Availability of Silicon Photonics Process Design Kit for Advanced Electro-Optic Polymer Integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2522574597","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522574597?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:30","pubTimestamp":1743165000,"startTime":"0","endTime":"0","summary":"Management team to attend the Optical Fiber Conference in San Francisco. DENVER, COLORADO / ACCESS Newswire / March 28, 2025 / Lightwave Logic, Inc.  , a technology platform company leveraging its proprietary electro-optic  polymers to transmit data at higher speeds with less power, today announced the controlled availability of its cutting-edge Process Design Kit . This PDK enables the integration of the Company's advanced EO polymers into Silicon Photonic Integrated Circuits  using Lightwave Logic's novel Back-End-of-Line  process.Despite the significant advancements in silicon photonics, scaling up to data rates of 200Gbps and 400Gbps presents inherent challenges. Traditional silicon photonics-based modulators face bandwidth limitations due to their reliance on charge-carrier effects, leading to increased power consumption and signal degradation at higher speeds. As data center and AI-driven networking demands continue to push for greater bandwidth efficiency, alternative materials ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lightwave-logic-announces-controlled-availability-123000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4148","BK4157","ALD","AEIS","LWLG","IE0031619046.USD"],"gpt_icon":0},{"id":"2522775321","title":"Closing Bell: Tech tumble and Trump tariffs trample Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2522775321","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522775321?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:37","pubTimestamp":1743061048,"startTime":"0","endTime":"0","summary":"Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday. Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too. to quickly recap, tech stocks took a pounding today on the back of a Wall Street dump across the sector, with AI behemoth Nvidia leading losses with a 6% stumble.According to reports, fears around the company’s business in China sent investors into a bit of a tizz, after the White House added several Chinese companies to a trade blacklist.Per a report in The Australian:The US has added dozens of Chinese companies to a trade blacklist over national security concerns. American businesses seeking to sell technology to these companies will need approval from the government.One of those companies blacklisted is Inspur Group – China’s largest server maker and one of the key Chinese customers of Nvidia.The Trump effect didn’t end there, his newly announced 25% US auto import tariffs  also wrought havoc on global markets, with Tesla, among other carma","market":"nz","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-128501522-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-128501522-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/news/closing-bell-tech-tumble-and-trump-tariffs-trample-thursday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ALD","BK4139","OPT"],"gpt_icon":0},{"id":"2522343337","title":"TSMC’s big US bet and China’s chip tool challenger","url":"https://stock-news.laohu8.com/highlight/detail?id=2522343337","media":"Financial Times","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522343337?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:30","pubTimestamp":1743060626,"startTime":"0","endTime":"0","summary":"This is Lauly, saying hi from the warm weather in Taipei.I can’t believe it’s already been weeks since I returned from Barcelona covering the annual Mobile World Congress, one of the biggest tech exhibitions in a year. As my colleague Annie Cheng Ting-Fang mentioned in her newsletter, we had to take cold showers for three nights at our hotel due to a plumbing issue, walked more than 10,000 steps at the expo and then had to endure subway disruptions for two straight days.Taiwan, which boasts the second-largest semiconductor industry in the world, has long taken a measure of comfort in its “Silicon Shield”, the concept that its crown jewel chip economy makes it too important for the US not to defend it should China ever invade. But what if the shie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tsmc-big-us-bet-china-073026026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234572021.USD","LU0061474960.USD","LU0345768153.USD","LU2250418816.HKD","ALD","LU2125154778.USD","FT","NVDY","NVIW.SI","IE00BN29S564.USD","LU1791710582.SGD","NVDX","SG9999014575.USD","3NVD.UK","LU2471134796.USD","IE00B5949003.HKD","LU0868494708.USD","LU1861127337.USD","LU0511384066.AUD","LU1923623000.USD","LU0320765059.SGD","NVDD","NVDS","LU2063271972.USD","LU1316542783.SGD","NVDA","IE00B19Z8W00.USD","SNVD.UK","LU0417517546.SGD","SG9999015952.SGD","LU1066051811.HKD","LU0225283273.USD","NVD2.UK","NVDU","NVD3.UK","LU2097344431.USD","LU0861579265.USD","LU1868836591.USD","LU2125909593.SGD","LU2756315664.SGD","LU0724617625.USD","LU0308772762.SGD","LU2236285917.USD","LU2191332357.HKD","2NVD.UK","NVDS.UK","NVD","LU1923622614.USD","NVDL","LU0096364046.USD"],"gpt_icon":1},{"id":"2522835349","title":"DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522835349","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522835349?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025. Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis . CUPERTINO, Calif., March 26, 2025 /PRNewswire/ --DURECT Corporation  today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.Results from the AHFIRM Phase 2b trial were published in NEJM Evidence in January 2025. In addition to highlighting the key findings from this study, the article also included new trial data, including subgroup analyses that explain regional differences in patient populations and in AH treatment regimens. Variations in time from hospitalization to first dose highlighted the importance of timely treatment in patients with severe AH. The full article can be accessed here. Top line d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/durect-corporation-reports-fourth-quarter-200500269.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/durect-corporation-reports-fourth-quarter-200500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","DRRX","ALD","BK4557"],"gpt_icon":0},{"id":"2521940494","title":"Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940494","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940494?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:45","pubTimestamp":1742503500,"startTime":"0","endTime":"0","summary":"Hypertrophic cardiomyopathy  is the most common human genetic cardiac disorder and can lead to serious complications including heart failure and sudden cardiac death. The preclinical study was financed through a grant by DZHK1 and conducted at the TUM University Hospital German Heart Center under a research collaboration2 between Poxel and the TUM University Hospital German Heart Center. Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, added: \"The findings of the pre-clinical study conducted in collaboration with Poxel represent a major step in the development of a novel therapeutic approach to treat hypertrophic cardiomyopathy, a severe and progressive disease that can lead to life-threatening cardiac events. Results obtained during this preclinical study showed that PXL065 may have the potential to improve the clinical outcomes for patients suffering from this genetic condition by reducing left ventr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-positive-results-preclinical-204500666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0122376428.USD","MPC","LU0368265418.SGD","BK4585","LU0788109394.HKD","LU0170899867.USD","HCM","BK4531","BK4138","BK4139","LU0300736492.USD","ALD","LU0456854461.SGD","LU0266512127.USD","IE00BSNM7G36.USD","PXXLF","LU0300736062.USD","BK4007"],"gpt_icon":0},{"id":"2520992675","title":"Ampol Limited (ASX:ALD) is favoured by institutional owners who hold 51% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2520992675","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520992675?lang=en_us&edition=fundamental","pubTime":"2025-03-19 11:25","pubTimestamp":1742354724,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Ampol implies that they have significant influence over the company's share price. 48% of the business is held by the top 25 shareholders. Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business. If you want to know who really controls Ampol Limited , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 51% to be precise, is institutions. In other words, the group stands to gain the most  from their investment into the company.Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Let's take a closer look to see what the different types of shareholders can tell us about Ampol.The definition of compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampol-limited-asx-ald-favoured-032524670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ALD.AU","BK7065","ALD"],"gpt_icon":0},{"id":"2514862721","title":"Ampol's (ASX:ALD) Shareholders Will Receive A Smaller Dividend Than Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862721","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862721?lang=en_us&edition=fundamental","pubTime":"2025-02-27 04:20","pubTimestamp":1740601254,"startTime":"0","endTime":"0","summary":"Ampol Limited's  dividend is being reduced from last year's payment covering the same period to A$0.05 on the 3rd of April. This payment takes the dividend yield to 2.5%, which only provides a modest boost to overall returns.Ampol's Projected Earnings Seem Likely To Cover Future Distributions. If it is predictable over a long period, even low dividend yields can be attractive. Based on the last payment, the company wasn't making enough to cover what it was paying to shareholders. Without profits and cash flows increasing, it would be difficult for the company to continue paying the dividend at this level.Analysts expect a massive rise in earnings per share in the next year. If recent patterns in the dividend continue, we could see the payout ratio reaching 27% which is fairly sustainable.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampols-asx-ald-shareholders-receive-202054234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7065","ALD","ALD.AU"],"gpt_icon":0},{"id":"2514374071","title":"Ampol Full Year 2024 Earnings: EPS: AU$0.51 (vs AU$2.30 in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514374071","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514374071?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:17","pubTimestamp":1740518277,"startTime":"0","endTime":"0","summary":"Ampol ( ASX:ALD ) Full Year 2024 Results Key Financial Results Revenue: AU$34.9b (down 7.6% from FY 2023). Net income...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-full-year-2024-earnings-eps-au051-vs-au230-in-fy-2023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2512488028","title":"Lam Research Ushers in New Era of Semiconductor Metallization with ALTUS® Halo for Molybdenum Atomic Layer Deposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488028","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512488028?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:00","pubTimestamp":1739973600,"startTime":"0","endTime":"0","summary":"Industry's First Molybdenum Deposition Solution for High-Volume Production Overcomes Limitations of Conventional Metals to Enable Chip Scaling for Advanced Applications. FREMONT, Calif., Feb. 19, 2025 /PRNewswire/ -- Lam Research Corp.  today unveiled ALTUS Halo, the world's first atomic layer deposition  tool that harnesses the capabilities of the metal molybdenum in the production of leading-edge semiconductors. Leveraging a range of patented innovations, ALTUS Halo delivers exceptional feature fill and high-precision deposition of low resistivity, void-free molybdenum metallization for advanced semiconductor devices. Currently in qualification and ramping with all leading chipmakers, ALTUS Halo represents the tipping point in a new age of semiconductor metallization, paving the way for future scaling of advanced memory and logic chips for tomorrow's AI, cloud computing and next-generation smart devices.Molybdenum Enables Low-Resistance Metallization Required for Next-Generation Chip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lam-research-ushers-era-semiconductor-140000846.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lam-research-ushers-era-semiconductor-140000846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0719512351.SGD","LU0348723411.USD","IE00B7KXQ091.USD","ALD","IE00BJJMRX11.SGD","LU0444971666.USD","IE00B775H168.HKD","IE00BN29S564.USD","IE00BQXX3F31.USD","LU0061474960.USD","BK4551","LU1069347547.HKD","LU1035773651.USD","BK4147","LU1670627923.USD","LRCX","LU1815336760.USD","IE00B4JS1V06.HKD","IE0005OL40V9.USD","LU1917777945.USD","LU0082616367.USD","LU2023250843.SGD","BK4543","IE00BFSS8Q28.SGD","IE00BQXX3C00.GBP","LU0957808578.USD","LU0476273544.USD","IE00BQXX3D17.EUR","LU1815333072.USD","BK4567","IE0004445015.USD","BK4588","BK4585","LU0444973449.USD","BK4533","BK4581","LU2106854487.HKD","IE00BFSS7M15.SGD","LU1974910355.USD","IE00BJJMRY28.SGD","LU0096362180.USD","LU0957791311.USD","LU1642822529.SGD","IE0009356076.USD","LU0061475181.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2511554960","title":"ALD SA (3AL) Receives a Hold from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2511554960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511554960?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:05","pubTimestamp":1739448353,"startTime":"0","endTime":"0","summary":"In a report released on February 11, Delphine Lee from J.P. Morgan maintained a Hold rating on ALD SA (3AL – Research Report), with a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ald-sa-3al-receives-a-hold-from-j-p-morgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ald-sa-3al-receives-a-hold-from-j-p-morgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0971096721.USD","LU1732800096.USD","LU2089283258.USD","IE00BKVL7J92.USD","BK4581","LU1548497426.USD","LU2271345857.HKD","LU0106261372.USD","BK4127","LU2347655156.SGD","LU0158827948.USD","LU2133065610.SGD","LU0006306889.USD","LU1074936037.SGD","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU2111349929.HKD","LU1720051108.HKD","LU1732799900.SGD","LU1363072403.SGD","BK4534","LU0795875086.SGD","LU0314104364.USD","LU2357305700.SGD","LU0158827781.USD","BK4588","LU0795875169.SGD","LU1989772923.USD","LU1668664300.SGD","BK4504","LU2089284900.SGD","BK4585","LU0106831901.USD","LU2023251221.USD","LU2028103732.USD","BK4516","ALD","LU0225283273.USD","LU0267386448.USD","LU1162221912.USD","LU0320765646.SGD","LU0912757837.SGD","LU0098860793.USD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2510593803","title":"Poxel Announces Results of its Combined General Meeting Held on February 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510593803","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510593803?lang=en_us&edition=fundamental","pubTime":"2025-02-12 03:28","pubTimestamp":1739302080,"startTime":"0","endTime":"0","summary":"POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announces that it held its Combined General Meeting on February 11, 2025, at 9;00 am CET at the Mercure Lyon Centre Chteau Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, France.The number of voting rights held by shareholders present or represented was 18,380,495, representing a quorum of 34.26%.Details on the voting results on all resolutions, the replay of the Combined General Meeting as well as the presentation that was made during the meeting, are available today on the Company’s website, in the Investors / Shareholder Info / Annual General Meeting Documents section.The resolutions related to the revised remuneration policy for corporate officers for 2025, as proposed by the Board of Directors, were ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-results-combined-general-192800649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PXXLF","BK4139","ALD"],"gpt_icon":0},{"id":"2510090891","title":"Is Veeco Instruments Inc. (VECO) the Best Small-Cap Semiconductor Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510090891","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510090891?lang=en_us&edition=fundamental","pubTime":"2025-02-11 03:06","pubTimestamp":1739214394,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Small-Cap Semiconductor Stocks to Buy Now.In this article, we are going to take a look at where Veeco Instruments Inc.  stands against the other small-cap semiconductor stocks.According to Deloitte's 2025 global semiconductor industry outlook, released on February 4, 2025, the semiconductor industry is set for a much better 2025, with projected sales reaching $697 billion, representing an 11.2% year-over-year growth. This projection suggests the industry is on track to achieve the widely accepted goal of $1 trillion in sales by 2030. Deloitte analysts also highlight that \"average\" chip stock performance over the past two years has been a \"tale of two markets\": Companies involved in the generative AI chip market have outperformed, while those in automotive, computer, smartphone, and communications semiconductors have lagged.At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veeco-instruments-inc-veco-best-190634548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","SAM","IE00B66KJ199.SGD","PSQ","ALD","MNQmain","IE00B19Z4B17.USD","TQQQ","SQQQ","QLD","BK4585","TSYW.SI","BK4168","GAA","BK4532","BK4588","HBM","USJW.SI","VECO","BK4147","BK4158","IE00B7SZL793.SGD","NQmain","USAW.SI",".IXIC","QID","NVIW.SI"],"gpt_icon":1},{"id":"2510658854","title":"Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510658854","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510658854?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192400,"startTime":"0","endTime":"0","summary":"Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023370/0/en/Tempest-Granted-Fast-Track-Designation-from-the-U-S-Food-and-Drug-Administration-for-Amezalpat-to-Treat-Patients-with-Hepatocellular-Carcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4225","IE00B5TLWC47.USD","ALD","BK4585","BK4006","BK4567","IE00BYQQ9H92.USD","OS","BK4588","BK4203","BK4183","HR","IE00BFXG0V08.USD","ODD","HCC","FAST","BK4104","BK4097"],"gpt_icon":0},{"id":"2509008994","title":"The one-year underlying earnings growth at Ampol (ASX:ALD) is promising, but the shareholders are still in the red over that time","url":"https://stock-news.laohu8.com/highlight/detail?id=2509008994","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509008994?lang=en_us&edition=fundamental","pubTime":"2025-02-08 07:35","pubTimestamp":1738971304,"startTime":"0","endTime":"0","summary":"The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/the-one-year-underlying-earnings-growth-at-ampol-asxald-is-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD","ALD.AU"],"gpt_icon":0},{"id":"2509855782","title":"MSA Safety Showcasing Automatic Leak Detection and Monitoring Expertise at AHR Expo","url":"https://stock-news.laohu8.com/highlight/detail?id=2509855782","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509855782?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:25","pubTimestamp":1738877100,"startTime":"0","endTime":"0","summary":"MSA to Feature FieldServer Gateways Designed to Enhance Network Protocol Connectivity. PITTSBURGH, Feb. 6, 2025 /PRNewswire/ --The spotlight on refrigerant leak detection, monitoring and reporting has never been brighter as the HVAC and refrigeration  industry navigates regulatory changes in their market. To help HVAC-R businesses address these changes, MSA Safety, Inc.  will be showcasing its leak detection and monitoring management solution capabilities at next week's AHR Expo in Orlando, Florida, February 10th through 12th.As one of the largest HVAC-R events, the AHR Expo connects industry leaders and experts with more than 50,000 professionals to discuss the latest trends and topics, while showcasing leading solutions and technologies.With an increased industry focus on tracking refrigerant usage and regulatory compliance, MSA Safety is showcasing itsParasense Refrigerant Tracking & Compliance Software. This cloud-based software offers refrigerant management and tracking tools desi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/msa-safety-showcasing-automatic-leak-212500525.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/msa-safety-showcasing-automatic-leak-212500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909916.SGD","LU2211815571.USD","LU0728928796.USD","LU1923622291.USD","AHR","LU0757428866.USD","BK4143","MSA","BK4225","LU0053671581.USD","LU1815336091.USD","ALD","LU2125909759.SGD"],"gpt_icon":0},{"id":"2506453211","title":"Adisyn completes $10 million placement to drive AI enabling semiconductor innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2506453211","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506453211?lang=en_us&edition=fundamental","pubTime":"2025-01-28 09:06","pubTimestamp":1738026379,"startTime":"0","endTime":"0","summary":"Placement proceeds to support Adisyn’s growth objectives. Incoming board member Kevin Crofton subscribes for 800,000 shares","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-24-AI1-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-24-AI1-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/tech/adisyn-completes-10-million-placement-to-drive-ai-enabling-semiconductor-innovation/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ALD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-19","symbol":"ALD","amount":0.075,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1550552400000},{"market":"US","date":"2019-01-22","symbol":"ALD","amount":0.095,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1548133200000},{"market":"US","date":"2018-12-24","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1545627600000},{"market":"US","date":"2018-11-20","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1542690000000},{"market":"US","date":"2018-10-23","symbol":"ALD","amount":0.09,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1540267200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-23","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-02-17","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-03-27","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-05-22","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-06-26","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{}}}